Your browser doesn't support javascript.
loading
Phosphate Coordination to Metal-Organic Layer Secondary Building Units Prolongs Drug Retention for Synergistic Chemoradiotherapy.
Luo, Taokun; Jiang, Xiaomin; Li, Jinhong; Nash, Geoffrey T; Yuan, Eric; Albano, Luciana; Tillman, Langston; Lin, Wenbin.
Afiliação
  • Luo T; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Jiang X; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Li J; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Nash GT; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Yuan E; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Albano L; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Tillman L; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
  • Lin W; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Angew Chem Int Ed Engl ; 63(16): e202319981, 2024 04 15.
Article em En | MEDLINE | ID: mdl-38381713
ABSTRACT
Chemoradiotherapy combines radiotherapy with concurrent chemotherapy to potentiate antitumor activity but exacerbates toxicities and causes debilitating side effects in cancer patients. Herein, we report the use of a nanoscale metal-organic layer (MOL) as a 2D nanoradiosensitizer and a reservoir for the slow release of chemotherapeutics to amplify the antitumor effects of radiotherapy. Coordination of phosphate-containing drugs to MOL secondary building units prolongs their intratumoral retention, allowing for continuous release of gemcitabine monophosphate (GMP) for effective localized chemotherapy. In the meantime, the MOL sensitizes cancer cells to X-ray irradiation and provides potent radiotherapeutic effects. GMP-loaded MOL (GMP/MOL) enhances cytotoxicity by 2-fold and improves radiotherapeutic effects over free GMP in vitro. In a colon cancer model, GMP/MOL retains GMP in tumors for more than four days and, when combined with low-dose radiotherapy, inhibits tumor growth by 98 %. The synergistic chemoradiotherapy enabled by GMP/MOL shows a cure rate of 50 %, improves survival, and ameliorates cancer-proliferation histological biomarkers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article